FTH · Faeth Therapeutics, Inc.

📣 What FTH Says Is Next

• in 2027 · “PIKTOR is also being evaluated in a Phase 1b/2 trial in HR+/HER2- advanced breast cancer (Study FTH-PIK-101), in which the first patient was dosed in April 2026 and interim data is anticipated in 2027.”
  Company press release, Aug 4, 2026 · SEC filing
• second half of 2026 · “PIKTOR is being evaluated in a Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201), with topline data anticipated in the second half of 2026.”
  Company press release, Aug 4, 2026 · SEC filing
• by year-end · “We look forward to reading out topline data from our Phase 2 PIK-201 trial in endometrial cancer, which is expected by year-end.” Mr. Parikh continued, “We are also excited to have expanded development of PIKTOR into its second indication with the first patient dosed in our PIK-101 trial in HR+ breast cancer in April.”
  Company press release, Aug 4, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

🧪 Trial & FDA Catalysts

• Sep 2028 · Phase 2 · Recruiting · Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppr
  Registry primary completion date, not a results date
• May 2029 · Phase 1/2 · Recruiting · Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- A
  Registry primary completion date, not a results date

📊 Drug Pipeline

Also used in these trials (approved or third-party drugs, not FTH's own candidates): Fulvestrant, Paclitaxel.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

FTH holds $186.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $13.2M/quarter from operations, an estimated runway of 42.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

• Cash runway 42 months
• ATM program on file since Jun 2026 +15
• Shelf registration (S-3ASR, Jun 2026) +10

Recent financing filings on SEC EDGAR:

• Jun 18, 2026 · Shelf registration with ATM program, up to $150M · S-3ASR
• Feb 18, 2026 · Private placement (8-K Item 3.02) · 8-K

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when FTH files for a raise →

👥 Who Owns FTH

Share count 25,840,425 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.